{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:54:17Z","timestamp":1758815657998,"version":"3.44.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["18OKG04"],"award-info":[{"award-number":["18OKG04"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.kint.2020.03.023","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T05:08:57Z","timestamp":1595308137000},"page":"289-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability"],"prefix":"10.1016","volume":"98","author":[{"given":"Esther","family":"Meijer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2020.03.023_bib1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2020.03.023_bib2","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.03.023_bib3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2020.03.023_bib4","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.03.023_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 Trial","volume":"11","author":"Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.03.023_bib6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.01520218","article-title":"Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease","volume":"13","author":"Edwards","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.03.023_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.03.023_bib8","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.03.023_bib9","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A\u00a0practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.03.023_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2020.03.023_bib11","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.03.023_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","article-title":"Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease","volume":"96","author":"Gansevoort","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.03.023_bib15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2020.03.023_bib16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2018.09.016","article-title":"Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan","volume":"73","author":"Kramers","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2020.03.023_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12882-018-0957-7","article-title":"Case report: a thiazide diuretic to treat polyuria induced by tolvaptan","volume":"19","author":"Kramers","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2020.03.023_bib18","doi-asserted-by":"crossref","first-page":"e88409","DOI":"10.1172\/jci.insight.88409","article-title":"Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus","volume":"1","author":"Efe","year":"2016","journal-title":"JCI insight"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525382030394X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525382030394X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:55:24Z","timestamp":1758761724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525382030394X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S008525382030394X"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2020.03.023","relation":{},"ISSN":["0085-2538"],"issn-type":[{"type":"print","value":"0085-2538"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2020.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}